Cambridge-based Momenta Pharmaceuticals has been granted a patent that will help the company advance its drug target for a generic form of Teva Pharmaceutical Industries’ multiple sclerosis treatment Copaxone, the Boston Business Journal reports.
The approval capped a good day for Momenta and a not-so-good one for Teva, which reported that profits fell short of investor expectations, the BBJ reports.
Read more: Momenta logs MS generic victory | Boston Business Journal